Cargando…

Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China

BACKGROUND: Anti-tuberculosis drug induced liver injury (ATLI) is emerging as a significant threat to tuberculosis control in China, though limited data is available about the burden of ATLI at population level. This study aimed to estimate the incidence of ATLI, to better understand its clinical fe...

Descripción completa

Detalles Bibliográficos
Autores principales: Shang, Penghui, Xia, Yinyin, Liu, Feiying, Wang, Xiaomeng, Yuan, Yanli, Hu, Daiyu, Tu, Dehua, Chen, Yixin, Deng, Peiyuan, Cheng, Shiming, Zhou, Lin, Ma, Yu, Zhu, Lizhen, Gao, Weiwei, Wang, Hongyuan, Chen, Dafang, Yang, Li, He, Pingping, Wu, Shanshan, Tang, Shaowen, Lv, Xiaozhen, Shu, Zheng, Zhang, Yuan, Yang, Zhirong, Chen, Yan, Li, Na, Sun, Feng, Li, Xiaoting, He, Yingjian, Garner, Paul, Zhan, Siyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130045/
https://www.ncbi.nlm.nih.gov/pubmed/21750735
http://dx.doi.org/10.1371/journal.pone.0021836
_version_ 1782207578939326464
author Shang, Penghui
Xia, Yinyin
Liu, Feiying
Wang, Xiaomeng
Yuan, Yanli
Hu, Daiyu
Tu, Dehua
Chen, Yixin
Deng, Peiyuan
Cheng, Shiming
Zhou, Lin
Ma, Yu
Zhu, Lizhen
Gao, Weiwei
Wang, Hongyuan
Chen, Dafang
Yang, Li
He, Pingping
Wu, Shanshan
Tang, Shaowen
Lv, Xiaozhen
Shu, Zheng
Zhang, Yuan
Yang, Zhirong
Chen, Yan
Li, Na
Sun, Feng
Li, Xiaoting
He, Yingjian
Garner, Paul
Zhan, Siyan
author_facet Shang, Penghui
Xia, Yinyin
Liu, Feiying
Wang, Xiaomeng
Yuan, Yanli
Hu, Daiyu
Tu, Dehua
Chen, Yixin
Deng, Peiyuan
Cheng, Shiming
Zhou, Lin
Ma, Yu
Zhu, Lizhen
Gao, Weiwei
Wang, Hongyuan
Chen, Dafang
Yang, Li
He, Pingping
Wu, Shanshan
Tang, Shaowen
Lv, Xiaozhen
Shu, Zheng
Zhang, Yuan
Yang, Zhirong
Chen, Yan
Li, Na
Sun, Feng
Li, Xiaoting
He, Yingjian
Garner, Paul
Zhan, Siyan
author_sort Shang, Penghui
collection PubMed
description BACKGROUND: Anti-tuberculosis drug induced liver injury (ATLI) is emerging as a significant threat to tuberculosis control in China, though limited data is available about the burden of ATLI at population level. This study aimed to estimate the incidence of ATLI, to better understand its clinical features, and to evaluate its impact on anti-tuberculosis (TB) treatment in China. METHODOLOGY/PRINCIPAL FINDINGS: In a population-based prospective study, we monitored 4,304 TB patients receiving directly observed treatment strategy (DOTS) treatment, and found that 106 patients developed ATLI with a cumulative incidence of 2.55% (95% Confidence Interval [CI], 2.04%–3.06%). Nausea, vomiting and anorexia were the top three most frequently observed symptoms. There were 35 (33.02%) ATLI patients with no symptoms, including 8 with severe hepatotoxicity. Regarding the prognosis of ATLI, 84 cases (79.25%) recovered, 18 (16.98%) improved, 2 (1.89%) failed to respond to the treatment with continued elevation of serum alanine aminotransferase, and 2 (1.89%) died as result of ATLI. Of all the ATLI cases, 74 (69.81%) cases changed their anti-TB treatment, including 4 (3.77%) cases with medication administration change, 21 (19.81%) cases with drugs replacement, 54 (50.94%) cases with therapy interruption, and 12 (11.32%) cases who discontinued therapy. In terms of treatment outcomes, 53 (51.46%) cases had TB cured in time, 48 (46.60%) cases had therapy prolonged, and 2 (1.94%) cases died. Compared with non-ATLI patients, ATLI patients had a 9.25-fold (95%CI, 5.69–15.05) risk of unsuccessful anti-TB treatment outcomes and a 2.11-fold (95%CI,1.23–3.60) risk of prolonged intensive treatment phase. CONCLUSIONS/SIGNIFICANCE: ATLI could considerably impact the outcomes of anti-TB treatment. Given the incidence of ATLI and the size of TB population in China, the negative impact is substantial. Therefore, more research and efforts are warranted in order to enhance the diagnosis and the prevention of ATLI.
format Online
Article
Text
id pubmed-3130045
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-31300452011-07-12 Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China Shang, Penghui Xia, Yinyin Liu, Feiying Wang, Xiaomeng Yuan, Yanli Hu, Daiyu Tu, Dehua Chen, Yixin Deng, Peiyuan Cheng, Shiming Zhou, Lin Ma, Yu Zhu, Lizhen Gao, Weiwei Wang, Hongyuan Chen, Dafang Yang, Li He, Pingping Wu, Shanshan Tang, Shaowen Lv, Xiaozhen Shu, Zheng Zhang, Yuan Yang, Zhirong Chen, Yan Li, Na Sun, Feng Li, Xiaoting He, Yingjian Garner, Paul Zhan, Siyan PLoS One Research Article BACKGROUND: Anti-tuberculosis drug induced liver injury (ATLI) is emerging as a significant threat to tuberculosis control in China, though limited data is available about the burden of ATLI at population level. This study aimed to estimate the incidence of ATLI, to better understand its clinical features, and to evaluate its impact on anti-tuberculosis (TB) treatment in China. METHODOLOGY/PRINCIPAL FINDINGS: In a population-based prospective study, we monitored 4,304 TB patients receiving directly observed treatment strategy (DOTS) treatment, and found that 106 patients developed ATLI with a cumulative incidence of 2.55% (95% Confidence Interval [CI], 2.04%–3.06%). Nausea, vomiting and anorexia were the top three most frequently observed symptoms. There were 35 (33.02%) ATLI patients with no symptoms, including 8 with severe hepatotoxicity. Regarding the prognosis of ATLI, 84 cases (79.25%) recovered, 18 (16.98%) improved, 2 (1.89%) failed to respond to the treatment with continued elevation of serum alanine aminotransferase, and 2 (1.89%) died as result of ATLI. Of all the ATLI cases, 74 (69.81%) cases changed their anti-TB treatment, including 4 (3.77%) cases with medication administration change, 21 (19.81%) cases with drugs replacement, 54 (50.94%) cases with therapy interruption, and 12 (11.32%) cases who discontinued therapy. In terms of treatment outcomes, 53 (51.46%) cases had TB cured in time, 48 (46.60%) cases had therapy prolonged, and 2 (1.94%) cases died. Compared with non-ATLI patients, ATLI patients had a 9.25-fold (95%CI, 5.69–15.05) risk of unsuccessful anti-TB treatment outcomes and a 2.11-fold (95%CI,1.23–3.60) risk of prolonged intensive treatment phase. CONCLUSIONS/SIGNIFICANCE: ATLI could considerably impact the outcomes of anti-TB treatment. Given the incidence of ATLI and the size of TB population in China, the negative impact is substantial. Therefore, more research and efforts are warranted in order to enhance the diagnosis and the prevention of ATLI. Public Library of Science 2011-07-05 /pmc/articles/PMC3130045/ /pubmed/21750735 http://dx.doi.org/10.1371/journal.pone.0021836 Text en Shang et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Shang, Penghui
Xia, Yinyin
Liu, Feiying
Wang, Xiaomeng
Yuan, Yanli
Hu, Daiyu
Tu, Dehua
Chen, Yixin
Deng, Peiyuan
Cheng, Shiming
Zhou, Lin
Ma, Yu
Zhu, Lizhen
Gao, Weiwei
Wang, Hongyuan
Chen, Dafang
Yang, Li
He, Pingping
Wu, Shanshan
Tang, Shaowen
Lv, Xiaozhen
Shu, Zheng
Zhang, Yuan
Yang, Zhirong
Chen, Yan
Li, Na
Sun, Feng
Li, Xiaoting
He, Yingjian
Garner, Paul
Zhan, Siyan
Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China
title Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China
title_full Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China
title_fullStr Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China
title_full_unstemmed Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China
title_short Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China
title_sort incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (atli) in china
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130045/
https://www.ncbi.nlm.nih.gov/pubmed/21750735
http://dx.doi.org/10.1371/journal.pone.0021836
work_keys_str_mv AT shangpenghui incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT xiayinyin incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT liufeiying incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT wangxiaomeng incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT yuanyanli incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT hudaiyu incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT tudehua incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT chenyixin incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT dengpeiyuan incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT chengshiming incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT zhoulin incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT mayu incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT zhulizhen incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT gaoweiwei incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT wanghongyuan incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT chendafang incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT yangli incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT hepingping incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT wushanshan incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT tangshaowen incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT lvxiaozhen incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT shuzheng incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT zhangyuan incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT yangzhirong incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT chenyan incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT lina incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT sunfeng incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT lixiaoting incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT heyingjian incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT garnerpaul incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina
AT zhansiyan incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina